
TuHURA Biosciences (NASDAQ: HURA) announced initial data from the first three patients in its open-label study of IFx-2.0 as an adjunctive therapy to Keytruda in first-line treatment of metastatic Merkel Cell Carcinoma (MCC).
According to TuHURA, results showed that each patient achieved a major objective anti-tumor response, with all three responses meeting the criteria for partial response. All responses were durable, as each of the responses were ongoing at the protocol-specified six-month assessment.
In a statement, Dr. James Bianco, president and CEO at TuHURA, commented, “While preliminary and only reported in three patients, these results highlight that it is feasible to utilize CT or ultrasound guided administration of IFx-2.0 safely to patients with large bulky and or deep-seated tumors. This is also the first time we have administered IFx-2.0 with Keytruda in the front-line treatment setting of patients with metastatic MCC and may serve as a proxy to the potential response rates in the ongoing randomized placebo-controlled Phase 3 trial, which is also being conducted in the front-line treatment of patients with advanced or metastatic MCC as an adjunct with Keytruda.”
Dr. Bianco continued, “Approximately 30% of patients with metastatic MCC present without cutaneous or superficial nodal involvement. If we continue to see this high response rate in patients in this trial, we will explore the potential to expand the number of patients in the trial and discuss with the FDA its potential to supplement the ongoing Phase 3 trial, should that study successfully meet the primary endpoint. We look forward to additional patient data in the coming months, and we will seek to present the data at an appropriate scientific conference next year.”






